Clik here to view.
Takeda Receives $38 Million Grant from the Bill & Melinda Gates Foundation to...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502), (“Takeda”) today announced a partnership with the Bill & Melinda Gates Foundation to support global polio eradication in...
View ArticleClik here to view.
Clik here to view.
Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic...
SEATTLE Acucela Inc. (Tokyo: 4589) (“Acucela”), a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of...
View ArticleClik here to view.
Collaborative Study of Whole Exome Sequencing Offers New Hope for Children...
SAN DIEGO Illumina, Inc. (NASDAQ: ILMN), Children’s National Health System and The University of Queensland (UQ) announced today that a study using whole exome sequencing (WES), a method to look at...
View ArticleClik here to view.
Illumina Registers MiSeqDx System in South Korea
SAN DIEGO Illumina, Inc. (NASDAQ: ILMN) today announced it has received a product approval certificate for the MiSeqDx® Instrument and the MiSeqDx Universal Kit with the Ministry of Food and Drug...
View ArticleClik here to view.
Cell Therapy Ltd. Grants Japan License To Daiichi Sankyo For Its Heart...
CARDIFF, Wales Cell Therapy Ltd. (CTL) today announced the granting of the Japan license for its innovative cardiac regeneration medicine, Heartcel™ (immuno-modulatory progenitor [iMP] cells) to...
View ArticleClik here to view.
Takeda Reports Results for Fiscal Year 2015 (April 2015 – March 2016) and...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502): FY2015: A year of turnaround to sustained growth; achieved full year management guidance • Underlying revenue up +3.4%...
View ArticleClik here to view.
武田薬品：2015年度（4-3月期）の連結業績および2016年度の連結業績予想について
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 （東証：4502）： 2015年度は持続的成長への転換点となり、年間マネジメントガイダンスを達成 売上収益の実質的な成長は、武田成長ドライバー（消化器系疾患領域、オンコロジー、中枢神経系疾患領域）の力強い伸長により、対前年度＋3.4％（財務ベースでは対前年度＋1.7％の18,074億円）を達成...
View ArticleClik here to view.
JHL Biotech Opens Innovative Biosimilars Manufacturing Facility in China
CHALFONT ST. GILES, United Kingdom & WUHAN, China JHL Biotech (JHL), a biopharmaceutical company, opened the world’s first KUBio™ biopharmaceutical manufacturing facility with single-use...
View ArticleClik here to view.
Clik here to view.
Nitto Signs Partnership Agreement with Daiichi Sankyo
OSAKA, Japan Japan’s leading diversified materials manufacturer Nitto Denko Corporation (TOKYO:6988)(ISIN:JP3684000007) today announced the signing of a partnership agreement with global...
View ArticleClik here to view.
Dr.Reddy’sLaboratories Announces the Appointment of Mr.Bharat Doshi as an...
HYDERABAD, India Mr. Bharat Doshi has been appointed as an Additional Independent Director on the Board of Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), effective May 11,...
View ArticleClik here to view.
Takeda Appoints New Chief Financial Officer, James Kehoe
OSAKA, Japan Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502) today announced the appointment of James Kehoe as Takeda’s new Chief Financial Officer and Corporate Officer, effective on...
View ArticleClik here to view.
武田薬品:新たなChiefFinancialOfficerの着任について
大阪 （ビジネスワイヤ） — 武田薬品（東証：4502）は、このたび、James Kehoe氏が2016年6月15日付で当社のコーポレート・オフィサー Chief Financial Officer（CFO）として着任しますのでお知らせします。Kehoe氏は東京本社に勤務し、社長兼Chief Executive Officer（CEO）のChristophe Weberに直接レポートします。...
View ArticleClik here to view.
Dr.Reddy’s Q4 and FY16 Financial Results
HYDERABAD, India Dr. Reddy’s Laboratories Ltd. (NYSE: RDY | BSE: 500124 | NSE: DRREDDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2016...
View ArticleClik here to view.
武田药品任命James Kehoe为新一任首席财务官
日本大阪 (美国商业资讯)–武田药品工业株式会社（简称“武田”）(TOKYO:4502)今天宣布任命James Kehoe为武田新一任首席财务官，2016年6月15日起生效。Kehoe先生的工作地点位于东京，他向武田总裁兼首席执行官Christophe Weber直接汇报。 武田总裁兼首席执行官Christophe Weber表示：“James...
View ArticleClik here to view.
Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO...
LONDON Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq:HCM) today announces that it has completed patient enrollment of FRESCO, its Phase III pivotal trial of fruquintinib (HMPL-013) in...
View ArticleClik here to view.
喜康生技在中国开张创新生物类似物制造设施
英国CHALFONT ST. GILES和中国武汉 (美国商业资讯) — 生物制药公司喜康生技(JHL Biotech, JHL)今天在中国武汉的一次剪彩仪式上启用了世界上首个采用单用途生物处理技术的KUBio™生物制药制造设施。 Smart News Releases（智能新闻稿）是一个多媒体平台。在此处查看完整新闻稿：...
View ArticleClik here to view.
喜康生技、中国に革新的なバイオシミラー製造施設を開設
英チャルフォントセントジャイルズ & 中国・武漢 （ビジネスワイヤ） — バイオ医薬品企業の喜康生技（JHLバイオテック）は本日、中国・武漢でテープカット式典を挙行し、シングルユース・バイオプロセス技術を用いる世界初のKUBio™バイオ医薬品製造施設を開設しました。 このSmart News...
View ArticleClik here to view.
武田公布2015财年（2015年4月-2016年3月）业绩以及2016财年预测
日本大阪 (美国商业资讯)–武田药品工业株式会社(TOKYO:4502)： 2015财年： 通向可持续增长的转折之年；实现全年的管理层指引 • 基础营收增长+3.4%（报告的营收增长率为+1.7%，至18,074亿日元），由武田增长引擎（胃肠药、肿瘤药、中枢神经系统药物和新兴市场）的强劲业绩所主导 • 基础核心盈利增长+8.1%（报告营业利润为1,308亿日元），得益于成本下降 •...
View Article